Canaccord analyst John Young raised the firm’s price target on Merit Medical to $125 from $102 and keeps a Buy rating on the shares. The firm expects the acquisition of EndoGastric Solutions to be accretive to both revenue growth and EPS in 2025 and beyond. Based on Merit’s $30M total estimate, Canaccord believes the asset is growing 15%-20% year over year, well above Merit’s current growth rate, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Systems Expands with Strategic Gastroesophageal Acquisition
- Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.®
- Merit Medical initiated with an Outperform at Baird
- Merit Medical management to meet with Barrington
- Merit Medical Systems to Announce Second Quarter 2024 Results on August 1, 2024